First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Lung Cancer Test Predicts Survival in Early Stages ... 2024 — A laboratory study provides evidence about how advanced age can be protective against cancer -- with implications for treating ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

A study found a "significant" link between the frequency of chest X-ray referrals and improved survival rates for lung cancer ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial ...

The New York State Senate has unanimously passed Senate Bill S. 2000, a significant step toward improving the early detection ...

Doctors at Delray Medical Center are combining AI and robotics to help detect lung cancer earlier and potentially save more ...

Onvida Health is bringing a new era of precision and early detection to lung cancer care in Yuma. The hospital has introduced ...